A phase II study of the efficacy of recombinant interferon gamma in relapsing ovarian adenocarcinoma - PubMed (original) (raw)
A phase II study of the efficacy of recombinant interferon gamma in relapsing ovarian adenocarcinoma
C E Welander et al. Am J Clin Oncol. 1988 Aug.
Abstract
Fourteen patients with relapsing ovarian cancer were treated with a regimen of intravenous interferon gamma (IFN gamma). During an initial induction phase, patients received 2 mg/m2 IFN gamma intravenously over 2 h daily for 5 days, repeated every 2 weeks for six courses. Patients who responded were continued on a maintenance phase, receiving 3 mg/m2 intravenously over 2 h, twice weekly every 2 weeks for 2 to 6 months. All patients had received prior cisplatin containing chemotherapy regimens. Of the 14 patients entered, 7 completed the six courses of the induction treatment. Four patients were clinical responders and continued on maintenance therapy. The most commonly reported toxicities included malaise, fever, and deteriorating performance status. There appears to be some clinically apparent antitumor activity demonstrated by this dosing schedule of interferon gamma in ovarian cancers.
Similar articles
- Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma.
Ajani JA, Rios AA, Ende K, Abbruzzese JL, Edwards C, Faintuch JS, Saks S, Gutterman JU, Levin B. Ajani JA, et al. J Biol Response Mod. 1989 Apr;8(2):140-6. J Biol Response Mod. 1989. PMID: 2499663 - A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
Ilson DH, Sirott M, Saltz L, Heelan R, Huang Y, Keresztes R, Kelsen DP. Ilson DH, et al. Cancer. 1995 May 1;75(9):2197-202. doi: 10.1002/1097-0142(19950501)75:9<2197::aid-cncr2820750902>3.0.co;2-s. Cancer. 1995. PMID: 7712428 Clinical Trial. - Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M. Oza AM, et al. Lancet Oncol. 2015 Jan;16(1):87-97. doi: 10.1016/S1470-2045(14)71135-0. Epub 2014 Dec 4. Lancet Oncol. 2015. PMID: 25481791 Clinical Trial.
Cited by
- Antiproliferative effects of interferon gamma in combination with alpha-difluoromethylornithine on human carcinoma cell cultures.
Klouche M, Kirchner H, Hölzel F. Klouche M, et al. J Cancer Res Clin Oncol. 1994;120(12):700-6. doi: 10.1007/BF01194266. J Cancer Res Clin Oncol. 1994. PMID: 7798293 - Cytokines and cancer.
Malik S, Waxman J. Malik S, et al. BMJ. 1992 Aug 1;305(6848):265-7. doi: 10.1136/bmj.305.6848.265. BMJ. 1992. PMID: 1382767 Free PMC article. No abstract available. - Inhibition of protein synthesis enhances the lytic effects of tumor necrosis factor alpha and interferon gamma in cell lines derived from gynecological malignancies.
Massad LS, Mutch DG, Kao MS, Powell CB, Collins JL. Massad LS, et al. Cancer Immunol Immunother. 1991;33(3):183-8. doi: 10.1007/BF01756140. Cancer Immunol Immunother. 1991. PMID: 1904315 Free PMC article. - Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial.
Windbichler GH, Hausmaninger H, Stummvoll W, Graf AH, Kainz C, Lahodny J, Denison U, Müller-Holzner E, Marth C. Windbichler GH, et al. Br J Cancer. 2000 Mar;82(6):1138-44. doi: 10.1054/bjoc.1999.1053. Br J Cancer. 2000. PMID: 10735496 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical